Brooks Laboratories Current Share Price | Brooks Laboratories Stock Screener
BROOKS
Pharmaceuticals
Brooks Laboratories Current Stock Price Today
Live Share Price NSE
₹61.53
▲
0.30 (0.49%)
Live Share Price BSE
₹61.39
▼
-0.84 (-1.35%)
As of September 18, 2026, the live Brooks Laboratories share price (NSE: BROOKS) is ₹61.53 on NSE and ₹61.39 on BSE, up 0.49% from the previous close, with shares trading between ₹61.02 and ₹63.89 in today's trading session, and a 52-week range of ₹37.11–₹145.94.
Browse BROOKS income statement to support your investment research.
Use the Brooks Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Brooks Laboratories Market Cap
₹193.50 Cr.
BROOKS P/E Ratio (TTM)
14.16
Brooks Laboratories P/B Ratio
1.53
EPS (TTM)
₹8.35
Dividend Yield
-
Debt to Equity
0.08
BROOKS 52 Week High
₹145.94
Brooks Laboratories 52 Week Low
₹37.11
Operating Margin
3.00%
Profit Margin
9.09%
BROOKS Revenue (TTM)
₹22.00
EBITDA
₹2.00
Net Income
₹2.00
Total Assets
₹148.00
Total Equity
₹123.00
Brooks Laboratories Current Share Price Chart
Track the current Brooks Laboratories share price and stock price with an interactive chart. Analyse BROOKS price trends, trading volume, historical performance, and volatility across different timeframes — the complete Brooks Laboratories stock quote in one place.
Brooks Laboratories Company Profile - Fundamental Screener
Screen Brooks Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for BROOKS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE650L01011
Brooks Laboratories Balance Sheet Screener
Screen BROOKS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 148 | 124 | 90 | 110 | 196 | 162 |
| Current Assets | 37 | 34 | 31 | 28 | 61 | 47 |
| Fixed Assets | 15 | 14 | 14 | 15 | 110 | 108 |
| Liabilities | ||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 4 | 3 | 2 | 3 | 13 | 19 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 123 | 98 | 66 | 74 | 134 | 79 |
| Share Capital | 30 | 30 | 26 | 25 | 25 | 25 |
| Reserves & Surplus | 93 | 69 | 39 | 49 | 63 | 54 |
Brooks Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Brooks Laboratories income statement and profit fundamentals.
Analyze BROOKS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Brooks Laboratories share price evaluation.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22 | 23 | 24 | 33 | 30 | 22 | 18 | 18 | 21 | 21 | 13 | 16 | 24 | 22 | 29 |
| Expenses | 20 | 24 | 25 | 22 | 21 | 16 | 27 | 20 | 24 | 22 | 16 | 20 | 25 | 25 | 32 |
| EBITDA | 2 | -1 | -1 | 10 | 9 | 6 | -9 | -2 | -3 | -2 | -4 | -4 | -1 | -3 | -4 |
| Operating Profit % | 3.00% | -6.00% | -5.00% | 12.00% | 11.00% | 4.00% | -54.00% | -11.00% | -16.00% | -7.00% | -29.00% | -25.00% | -5.00% | -15.00% | -14.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit Before Tax | 2 | -2 | -1 | 10 | 8 | 6 | -10 | -2 | -4 | -2 | -4 | -5 | -2 | -4 | -7 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Net Profit | 2 | -2 | -2 | 10 | 8 | 6 | -10 | -2 | -4 | -2 | -4 | -5 | -2 | -4 | -6 |
| EPS | 0.52 | -0.61 | -0.54 | 3.25 | 2.71 | 1.87 | -3.77 | -0.94 | -1.51 | -0.82 | -1.75 | -1.81 | -0.60 | -1.51 | -1.46 |
Brooks Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen BROOKS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|---|
| Operating Activities | 9 | 3 | -10 | -15 | -37 | 5 |
| Investing Activities | -3 | -45 | 0 | 1 | -25 | -5 |
| Financing Activities | 0 | 42 | 10 | 11 | 64 | 1 |
| Net Cash Flow | 7 | 0 | 0 | -3 | 2 | 1 |
Brooks Laboratories Shareholding Pattern Screener
See Brooks Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Brooks Laboratories promoter holding and ownership changes for BROOKS on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Jan | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 63.59% |
| FII Holding | 0.17% | 0.00% | 0.00% | 0.05% | 0.00% | 0.01% | 0.09% | 0.00% |
| DII Holding | 10.38% | 10.38% | 9.90% | 10.38% | 10.38% | 10.38% | 10.38% | 3.86% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.56% | 30.73% | 32.13% | 31.86% | 32.01% | 31.70% | 31.84% | 25.55% |
| Other Holding | 5.28% | 6.27% | 5.35% | 5.08% | 4.99% | 5.30% | 5.07% | 7.00% |
| Shareholder Count | 10,741 | 11,161 | 10,374 | 10,537 | 10,317 | 10,078 | 10,532 | 11,432 |
Brooks Laboratories Share Dividend Screener - Share Yield Analysis
Check Brooks Laboratories dividend history with payout and yield data.
View Brooks Laboratories dividend details including ex-dates and amounts for BROOKS stock.
Brooks Laboratories Stock Index Membership
See which indices include Brooks Laboratories stock.
Check BROOKS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Brooks Laboratories Market Events Screener - Corporate Actions
Get Brooks Laboratories corporate actions including splits, bonuses, and buybacks.
Check Brooks Laboratories stock events that may affect BROOKS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-03 | 2026-09-03 | Annual General Meeting | NA | 6.74% |
| 2026-08-13 | 2026-08-13 | Quarterly Result Announcement | NA | 3.27% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 21.52% |
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | -5.52% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 4.54% |
| 2025-09-26 | 2025-09-26 | Annual General Meeting | NA | -6.26% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -1.89% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | 0.04% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -11.44% |
| 2025-01-11 | 2025-01-11 | Extraordinary General Meeting | NA | 18.38% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | -5.92% |
| 2024-09-19 | 2024-09-19 | Annual General Meeting | NA | 24.65% |
| 2023-09-21 | 2023-09-21 | Annual General Meeting | NA | 6.27% |
| 2023-07-28 | 2023-07-28 | Rights | 1:16 | 12.52% |
| 2020-02-11 | Rights | 9:20 | - |
Brooks Laboratories Competitors Screener - Peer Comparison
Screen BROOKS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Brooks Laboratories Company Announcements - News Screener
Screen BROOKS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-08 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-03 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-21 | Addendum To The Notice Of 24Th Annual General Meeting Of The Company. | - |
| 2026-08-21 | Reg. 34 (1) Annual Report. | - |
| 2026-08-17 | Intimation Of Record Date E-Voting Dates And Book Closure Date | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-13 | Results - Financial Results For June 30 2026. | - |
| 2026-08-13 | Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday 13Th August 2026 | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-12 | Letter To The Shareholders - Annual Report For The FY 2025-26. | - |
| 2026-08-12 | Shareholder Meeting- AGM On 3Rd September 2026. | - |
| 2026-08-12 | Reg. 34 (1) Annual Report. | - |
| 2026-08-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-06 | Board Meeting Intimation for Under Regulation 29 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) | - |
| 2026-07-17 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-07-16 | Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements | - |
| 2026-07-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-02 | Announcement Under Regulation 30 Of The SEBI (LODR) Regulations 2015 - Incorporation Of Wholly Owned Subsidiary. | - |
| 2026-06-23 | Closure of Trading Window | - |